Inspire Investing LLC Grows Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Inspire Investing LLC grew its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 23.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,308 shares of the company’s stock after purchasing an additional 4,018 shares during the quarter. Inspire Investing LLC’s holdings in Syndax Pharmaceuticals were worth $410,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Syndax Pharmaceuticals by 13.6% in the first quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock valued at $117,262,000 after purchasing an additional 591,631 shares in the last quarter. Sofinnova Investments Inc. grew its holdings in Syndax Pharmaceuticals by 33.9% during the 2nd quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company’s stock valued at $44,215,000 after buying an additional 545,129 shares in the last quarter. StemPoint Capital LP increased its position in shares of Syndax Pharmaceuticals by 0.6% during the first quarter. StemPoint Capital LP now owns 1,100,988 shares of the company’s stock valued at $26,204,000 after buying an additional 6,494 shares during the period. Millennium Management LLC lifted its holdings in shares of Syndax Pharmaceuticals by 56.3% in the second quarter. Millennium Management LLC now owns 1,065,508 shares of the company’s stock worth $21,875,000 after buying an additional 383,634 shares in the last quarter. Finally, Iron Triangle Partners LP bought a new position in shares of Syndax Pharmaceuticals in the first quarter valued at approximately $23,159,000.

Analysts Set New Price Targets

A number of research firms recently weighed in on SNDX. JPMorgan Chase & Co. decreased their target price on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. HC Wainwright increased their price objective on Syndax Pharmaceuticals from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Bank of America boosted their target price on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Stifel Nicolaus raised their price target on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, Citigroup boosted their price objective on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, August 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.78.

Syndax Pharmaceuticals Trading Down 0.9 %

Shares of NASDAQ SNDX opened at $19.71 on Friday. The stock’s 50-day moving average is $19.33 and its 200 day moving average is $20.59. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -5.83 and a beta of 0.91. Syndax Pharmaceuticals, Inc. has a 1-year low of $11.22 and a 1-year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.11. The business had revenue of $3.50 million for the quarter. The business’s quarterly revenue was up 3499999990.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.64) earnings per share. On average, analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.66 EPS for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).